Incretin Mimetics (GLP-1 Agonists): Incretin mimetics are a new group of injectable drugs for type 2 diabetes treatment. Incretin mimetics are agents that act like incretin hormones such as glucagon-like peptide-1 (GLP-1).
The drugs, also commonly known as glucagon-like peptide 1 (GLP-1) receptor agonists They bind to GLP-1 receptors and stimulate glucose-dependent insulin release, therefore act as antihyperglycemics. Incretin mimetics are only used to treat type 2 diabetes.
Incretin mimetics also slow gastric emptying and as a result, prevent the steep rise in post-prandial blood glucose levels.
How Incretin Mimetics (GLP-1 Agonists) work?
They work by mimicking, the functions of the natural incretin hormones in the body that assist lower post-meal blood sugar levels.
- Stimulating the discharge of insulin by the pancreas subsequent eating, even before blood sugars start to rise.
- Repressing the discharge of glucagon by the pancreas. Glucagon is a hormone that induces the liver to release its stored sugar within the bloodstream.
- Decreasing glucose absorption into the bloodstream by diminishing the speed at which the stomach empties following eating, consequently making you feel more satisfied after a meal.
These outcomes are in direct reply to the presence of carbohydrate in the gut and consequently, the chance of notable hypoglycemia occurring is unlikely unless utilized in combination with other hypoglycemic medications.
Drugs in the Incretin Mimetics (GLP-1 Agonists)
- Bydureon, Byetta (Exenatide) – taken once weekly
- Byetta (Exenatide) – taken twice daily
- Victoza (lixisenatide) – taken once daily
- Victoza (Liraglutide) – taken once daily
- Trulicity (Dulaglutide) – taken once weekly
Side effects of Incretin Mimetics (GLP-1 Agonists)
Possible side effects of incretin mimetics combine:
- Nausea and upset stomach.
- Feeling less hungry.
- Heartburn and indigestion.
- Increased sweating